Christie Williamson, MD
Neurology · Lancaster, SCNPI 1912926544
Payments from drug & device makers
Across 403 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$880
- Alkermes, Inc.$831
- Teva Pharmaceuticals USA, Inc.$696
- Johnson & Johnson$675
- AbbVie$610
- plus $2K from 10 others
What the payments were for
- Food & beverage$6,21598%
- Education$1222%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 70 | $1,099 |
| Neurocrine Biosciences, Inc. | 57 | $880 |
| Alkermes, Inc. | 44 | $831 |
| Teva Pharmaceuticals USA, Inc. | 54 | $696 |
| Johnson & Johnson | 41 | $675 |
| AbbVie(2 entities) | 45 | $610 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $407 |
| E.r. Squibb & Sons, L.L.C. | 19 | $300 |
| Vanda Pharmaceuticals Inc. | 13 | $210 |
| Sunovion Pharmaceuticals Inc. | 13 | $176 |
| Lundbeck LLC | 9 | $153 |
| Indivior Inc. | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $69 |
| Noven Therapeutics, LLC | 4 | $58 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
How this compares
$6,337 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 18 | $150,325 |
| Invega SustennaPaliperidone Palmitate | 34 | $118,759 |
| Abilify MaintenaAripiprazole | 41 | $109,978 |
| VraylarCariprazine Hcl | 24 | $34,046 |
| CaplytaLumateperone Tosylate | 12 | $21,740 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,144 |
| Aripiprazole | 77 | $9,513 |
| Paliperidone ErPaliperidone | 21 | $6,857 |
| Clozapine | 15 | $2,278 |
| Ziprasidone Hcl | 40 | $1,909 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 34 | $1,794 |
| Fluvoxamine Maleate | 15 | $1,784 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 53 | $1,713 |
| Buspirone Hcl | 82 | $1,564 |
| Duloxetine Hcl | 80 | $1,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $880 | $150,32518 claims |
| Johnson & JohnsonInvega Sustenna | $675 | $118,75934 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,099 | $109,97841 claims |
| AbbVieVraylar | $610 | $34,04624 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $407 | $21,74012 claims |
| Alkermes, Inc.Lybalvi | $831 | $17,14411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.
Other neurology in Lancaster
- Mary HughesGreenville$6.3M
- William McElveenColumbia$3.7M
- Robert CarlileSummerville$2.3M
- Andrew KeeganCharleston$2.2M
- Paul MazzeoPort Royal$1.7M
- Vanessa HinsonCharleston$1.5M
- David SticklerNorth Charleston$1.2M
- Katherine RuzhanskyCharleston$1.1M
- Nicholas MilanoCharleston$1.1M
- Howard MandellRock Hill$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.